Zhicheng Yan
Zhicheng Yan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Hosseyni
Late Clinical Development Cellular Therapy, Bristol Myers Squibb, Boudry, Switzerland
11 shared publications - Hongxiang Hu
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA
11 shared publications - Julia Piasecki
Cancer Immunology and Cell Therapy TRC, Bristol Myers Squibb, Seattle, Washington
11 shared publications - Ken Ogasawara
Bristol Myers Squibb, Princeton, USA
11 shared publications - Simon Zhou
Research and Pharmacology, Aurinia Pharmaceuticals, Rockville, Maryland
11 shared publications - Xianghong Liu
Translational Medicine and Clinical Pharmacology, Bristol Myers Squibb, Summit, New Jersey
11 shared publications
Latest Publications
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Covariate selection process via Monolix
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Covariate selection process via Monolix
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Correlation between continuous covariates
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Correlation between continuous covariates
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Orva-cel pharmacokinetic profile by qPCR
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Orva-cel pharmacokinetic profile by qPCR
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Data from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Purpose:Orvacabtagene autoleucel (orva-cel; JCARH125), a chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen, was evaluated in patients with relapsed/refractory multiple myeloma in the EVOLVE phase I/II study (NCT03430011). We applied a modified piecewise model to characterize orva-cel transgene kinetics and assessed the impact of various covariates on its pharmacokinetics (PK).Experimental Design:The population PK analysis included 159 patients from the EVOLVE study. Traditional piecewise models, employing a first-order expansion rate with or without lag time followed by a biexponential contraction phase, were compared with a modified model incorporating a cell number-dependent expansion phase aligned with cellular physiology. Covariates assessed encompassed baseline demographics, dose levels (50–600 × 106 CD3+ chimeric antigen receptor+ T cells), prior/concomitant medications, baseline disease burden, and antitherapeutic antibody status.Results:Traditional piecewise models failed to accurately describe maximum orva-cel transgene level (Cmax) and underestimated the time to Cmax (Tmax). Our modified model incorporating a cell number–dependent expansion rate outperformed traditional models by (i) more accurately capturing the cellular expansion phase and (ii) yielding a Tmax that closely matches observed values. Additionally, dose level, percentage of plasma cells in bone marrow, and treatment-induced antitherapeutic antibody were identified as statistically significant covariates and associated with orva-cel expansion and/or persistence.Conclusions:Orva-cel PK was adequately described by the modified piecewise model incorporating a cell number–dependent expansion phase, which aligns closely with T-cell biology.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Purpose:Orvacabtagene autoleucel (orva-cel; JCARH125), a chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen, was evaluated in patients with relapsed/refractory multiple myeloma in the EVOLVE phase I/II study (NCT03430011). We applied a modified piecewise model to characterize orva-cel transgene kinetics and assessed the impact of various covariates on its pharmacokinetics (PK).Experimental Design:The population PK analysis included 159 patients from the EVOLVE study. Traditional piecewise models, employing a first-order expansion rate with or without lag time followed by a biexponential contraction phase, were compared with a modified model incorporating a cell number-dependent expansion phase aligned with cellular physiology. Covariates assessed encompassed baseline demographics, dose levels (50–600 × 106 CD3+ chimeric antigen receptor+ T cells), prior/concomitant medications, baseline disease burden, and antitherapeutic antibody status.Results:Traditional piecewise models failed to accurately describe maximum orva-cel transgene level (Cmax) and underestimated the time to Cmax (Tmax). Our modified model incorporating a cell number–dependent expansion rate outperformed traditional models by (i) more accurately capturing the cellular expansion phase and (ii) yielding a Tmax that closely matches observed values. Additionally, dose level, percentage of plasma cells in bone marrow, and treatment-induced antitherapeutic antibody were identified as statistically significant covariates and associated with orva-cel expansion and/or persistence.Conclusions:Orva-cel PK was adequately described by the modified piecewise model incorporating a cell number–dependent expansion phase, which aligns closely with T-cell biology.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Comparison of parameters, estimated log-likelihood, and information criteria among different structural models
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Comparison of parameters, estimated log-likelihood, and information criteria among different structural models
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Orva-cel pharmacokinetic profile by flow cytometry (a) and changes in the composition of CAR-T cells post-infusion (b).
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Orva-cel pharmacokinetic profile by flow cytometry (a) and changes in the composition of CAR-T cells post-infusion (b).
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Correlation between continuous covariates and simulated individual parameters
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Correlation between continuous covariates and simulated individual parameters
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
PK parameters of orva-cel by dose level
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
PK parameters of orva-cel by dose level
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Comparison of kinetic model parameters across CAR T-cell therapies
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Comparison of kinetic model parameters across CAR T-cell therapies